Shanghai Bio-Heart Biological Technology (2185.HK) - The Bubble Will Eventually Burst
156 Views26 Oct 2022 08:38
Bio-heart’s core products lack competitiveness, with high uncertainties in commercialization outlook. High valuation is maintained so as to get listed in A-share, but the bubble will eventually burst.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (May.19) - "Hedge Logic" Of CXO, Beijing's DRG+VBP Policy, Zylox-Tonbridge21 May 2023
- China Healthcare Weekly (May.12) - Three Globalization Strategies, GLP-1/Weight Loss Drug, Bio-Heart14 May 2023
- China Healthcare Weekly (Oct28)-OK Lens VBP, Time Required for Biotech to Make Profit, World Changes30 Oct 2022
- Shanghai Bio-Heart Biological Technology (2185.HK) - The Bubble Will Eventually Burst26 Oct 2022
- Interpretation of the 20th National Congress of the CPC and the Impact on China Healthcare24 Oct 2022
- Microport Scientific (853.HK) - Underperformance Would Be the Norm20 Oct 2022
- Pre-IPO Shanghai Bio-Heart Biological Technology - Conservative About the Outlook03 Nov 2021
x